Drug Information

Drug (ID: DG01525) and It's Reported Resistant Information

• Name: IRAK-1 or IRAK-4 inhibitors
• Synonyms: IRAK-1-4 Inhibitor I; 509093-47-4; IRAK-1/4 Inhibitor; IRAK-1/4 Inhibitor I; N-[1-(2-morpholin-4-ylethyl)benzimidazol-2-yl]-3-nitrobenzamide; Interleukin-1 Receptor-Associated-Kinase-1/4 Inhibitor; CHEMBL379787; N-(1-(2-morpholinoethyl)-1H-benzo[d]imidazol-2-yl)-3-nitrobenzamide; N-[1-[2-(4-morpholinyl)ethyl]-1H-benzimidazol-2-yl]-3-nitrobenzamide; IRAK-1-4 Inhibitor; IRAK1/4 Inhibitor I; MLS006010636; GTPL5990; SCHEMBL3600534; DTXSID50475143; HMS3229G05; HMS3263A20; HMS3744A07; BCP16164; EX-A1254; Tox21_501049; 3747AH; BDBM50184706; MFCD09752602; s6598; ZINC16052821; AKOS026750497; Benzamide, N-[1-[2-(4-morpholinyl)ethyl]-1H-benzimidazol-2-yl]-3-nitro-; CCG-206760; CS-0704; LP01049; SDCCGSBI-0086683.P002; NCGC00186035-01; NCGC00186035-02; NCGC00186035-03; NCGC00186035-04; NCGC00186035-10; NCGC00261734-01; BS-17437; HY-13329; SMR001456469; J3.545.430F; F17398; IRAK-1/4 Inhibitor I, >=98% (HPLC), solid; Q27078097; 1-[2-(4-Morpholinyl)ethyl]-2-(3-nitrobenzoylamino)-1H-benzoimidazole; 3-nitro-N-(1-(2-morpholin-4-yl-ethyl)-1H-benzoimidazol-2-yl)-benzamide; N-{1-[2-(morpholin-4-yl)ethyl]-1H-1,3-benzodiazol-2-yl}-3-nitrobenzamide
• Indication:
  In total 1 Indication(s)
  Psoriasis vulgaris [ICD-11: EA90]; Investigative; [1]
• Target: .; NOUNIPROTAC; [1]
• Formula: 5
• IsoSMILES: C1COCCN1CCN2C3=CC=CC=C3N=C2NC(=O)C4=CC(=CC=C4)[N+](=O)[O-]
• InChI: InChI=1S/C20H21N5O4/c26-19(15-4-3-5-16(14-15)25(27)28)22-20-21-17-6-1-2-7-18(17)24(20)9-8-23-10-12-29-13-11-23/h1-7,14H,8-13H2,(H,21,22,26)
• InChIKey: QTCFYQHZJIIHBS-UHFFFAOYSA-N
• PubChem CID: 11983295
• TTD Drug ID: D0I3XG

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Mature B-cell neoplasms/lymphoma [ICD-11: 2A85]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Myeloid differentiation primary response protein MyD88 (MYD88) [1]

• Molecule Alteration: Missense mutation; p.L265P (c.794T>C)
• Sensitive Disease: Mantle cell lymphoma [ICD-11: 2A85.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Blood; N.A.
• Experiment for Molecule Alteration: DNA sequencing assay
• Mechanism Description: The missense mutation p.L265P (c.794T>C) in gene MYD88 cause the sensitivity of IRAK-1 or IRAK-4 inhibitors by unusual activation of pro-survival pathway

References

• Ref 1: MYD88 L265P somatic mutation in Waldenstr m's macroglobulinemiaN Engl J Med. 2012 Aug 30;367(9):826-33. doi: 10.1056/NEJMoa1200710.